Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Reproductive Health Services

 
In compliance with the decisions of the International Conference on Population and Development in 1994 on behalf of the Government of Lebanon, the “Reproductive Health Program” was established at the Ministry of Public Health and supported by the United Nations Population Fund (UNFPA) under the umbrella of primary health care with a clear strategy between 1998 and 2001. The program is still ongoing through its integration within the primary health care department.

The Ministry of Public Health / Primary Health Care Department in collaboration with UNFPA provides various services regarding reproductive health and family planning in agreement with the joint annual work plan signed between the two parties.

The health services can be summarized in the following categories:
  • Family planning
  • Safe motherhood and Newborn Health
  • Diagnostic & Preventive Check-ups
  • Screening for Reproductive system diseases and reproductive tract cancers

I. Reproductive Health Services
The primary health care department provides preventive services in order to improve the health of the family (women, children, youth and men) through:
  • Providing reproductive health medications and supplies through PHC centers, including 57 health centers / clinics outside the primary health care network, and providing reproductive health services to the displaced in order to improve women's health and prevent unwanted pregnancies.
  • Delivering reproductive health information to beneficiaries through awareness and education programs which are provided by the primary health care centers within and outside the centers.
  • Providing equipment that enables early detection of reproductive system diseases (early detection of breast cancer, cervical cancer).
  • Encouraging pregnant women to receive a minimum of 4 visits during pregnancy and one postnatal visit.
  • Developing the capacity of service providers in primary health care centers based on the clinical protocols for reproductive health.
  • Preparing governmental hospitals to receive emergency obstetric cases.
  •  Equipping governmental hospitals to receive high-risk pregnancies.
  •  Capacity building of service providers to deal with survivors of sexual violence and refer them to relevant associations.
  • Capacity building of service providers of provision of equipment for primary health care centers and hospitals to address cases of rape and refer survivors to the relevant associations.
 

II. Antenatal and Postnatal Care Services:
The primary health care department offers as well antenatal and postnatal care services for pregnant Lebanese and non-Lebanese women across Lebanon as part of the reproductive health services. These services were supported by the formulation of the ‘’Service Delivery Guidelines’’, which were followed by consecutive training for primary health care (PHC) centers’ staff across Lebanon upon implementation.

The antenatal and postnatal care services offered by the PHC centers consist of the following:
All pregnant women visiting the centers should receive:
  1.  Minimum of 4 antenatal care services
  2.  2 Echography during pregnancy
  3.  1 postnatal visit
  4.  Coverage of vaccination for newborn of followed up mothers (according to the National Vaccination Calendar)
  5.  Provision of Reproductive Health drugs and supplies to all PHC centers, in addition to 64 Reproductive Health dispensaries supported by International NGOs to serve the displaced Syrians.
 

III. Service Delivery Guidelines for Reporoductive Health Care:
MoPH with the support of UNFPA and in collaboration with the Lebanese Society of Obstetrics & Gynecology (LSOG) launched " The Revised Version of the Service Delivery Guidelines for Reproductive Health" in June 2015, which aimed at improving the knowledge and skills of service providers, in order to ensure the provision of reproductive health services that meet women's, men's and youth's needs in Lebanon.

Accordingly, the first phase of training took place from July to September, with 275 physicians and health care workers, including: 160 paramedical specialties, 88 medical and 27 humanitarian actors.

The training aims to improve the knowledge, skills and confidence of health workers to ensure that reproductive health needs of women, men adults and youth are met in normal setting and in the case of crises.
 
IV. Project Reports:
    1
ATC Name B/G Ingredients Dosage Form Price
J01DD13 ZAKON G Cefpodoxime (proxetil) - 100mg/5ml 100mg/5ml Powder for suspension 1,116,733 L.L
P02CA03 ZALBENDOL G Albendazole - 200mg 200mg Tablet 127,985 L.L
C08DB01 ZALDEM G Diltiazem HCl - 60mg 60mg Tablet, scored 199,657 L.L
C08DB01 ZALDEM CR G Diltiazem HCl - 180mg 180mg Capsule, controlled release 966,287 L.L
C08DB01 ZALDEM CR G Diltiazem HCl - 120mg 120mg Capsule, controlled release 517,059 L.L
C08DB01 ZALDEM CR G Diltiazem HCl - 240mg 240mg Capsule, controlled release 1,002,123 L.L
N02AJ13 ZALDIAR B Paracetamol - 325mg, Tramadol - 37.5mg Tablet, film coated 704,173 L.L
S01GX08 ZALERG G Ketotifen - 0.25mg/ml 0.25mg/ml Drops solution 446,156 L.L
N05AX12 ZALONIL G Aripiprazole - 10mg 10mg Tablet, orodispersible 1,988,887 L.L
N05AX12 ZALONIL G Aripiprazole - 15mg 15mg Tablet, orodispersible 2,426,980 L.L
L01XX44 ZALTRAP BioTech Aflibercept - 100mg/4ml 100mg/4ml Injectable concentrate for solution 35,658,713 L.L
L01XX44 ZALTRAP BioTech Aflibercept - 100mg/4ml 100mg/4ml Injectable concentrate for solution 35,658,713 L.L
L01XX44 ZALTRAP BioTech Aflibercept - 200mg/8ml 200mg/8ml Injectable concentrate for solution 63,807,499 L.L
L01XX44 ZALTRAP BioTech Aflibercept - 200mg/8ml 200mg/8ml Injectable concentrate for solution 63,807,499 L.L
B01AF01 ZARLAN G Rivaroxaban - 15mg 15mg Tablet, film coated 2,015,764 L.L
B01AF01 ZARLAN G Rivaroxaban - 15mg 15mg Tablet, film coated 1,343,843 L.L
B01AF01 ZARLAN G Rivaroxaban - 20mg 20mg Tablet, film coated 1,343,843 L.L
B01AF01 ZARLAN G Rivaroxaban - 10mg 10mg Tablet, film coated 1,439,255 L.L
L03AA02 ZARZIO BioTech Filgrastim - 300mcg/0.5ml 30MU/0.5ml Injectable solution 13,053,190 L.L
L03AA02 ZARZIO BioTech Filgrastim - 300mcg/0.5ml 30MU/0.5ml Injectable solution 13,053,190 L.L
L01DB06 ZAVEDOS B Idarubicin HCl - 10mg 10mg Injectable freeze dried material 12,071,013 L.L
J01DD52 ZAVICEFTA B Ceftazidime - 2g, Avibactam - 0.5g Injectable powder for concentrate for solution 101,659,975 L.L
N03AF04 ZEBINIX B Eslicarbazepine acetate - 800mg 800mg Tablet 10,075,439 L.L
N06AB10 ZELAX 10 G Escitalopram (oxalate) - 10mg 10mg Caplet 833,182 L.L
N06AB10 ZELAX 20 G Escitalopram (oxalate) - 20mg 20mg Caplet 1,544,075 L.L
L01EC01 ZELBORAF B Vemurafenib - 240mg 240mg Tablet, film coated L.L
L01EC01 ZELBORAF B Vemurafenib - 240mg 240mg Tablet, film coated 142,041,587 L.L
C10AX09 ZEMIL G Ezetimibe - 10mg 10mg Tablet 944,529 L.L
P02CA03 ZENTEL B Albendazole - 400mg 400mg Tablet 169,324 L.L
R03AK12 ZEPHIRUS B Salmeterol - 20mcg, Budesonide - 120mcg Capsule, inhalation 1,412,378 L.L
    1
Sitemap
© Copyrights reserved to Ministry of Public Health 2026